Vaxart Inc (VXRT)

$0.32 0.00 (N/A)
Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
170 Harbor Way, Suite 300, South San Francisco, United States
BrutisWalter
BrutisWalter Feb. 3 at 7:50 PM
$VXRT I Personally DON'T trust Vaxart Management Team to do anything above board! They are the Crooks the Crooks DON'T TRUST!!
0 · Reply
SavedByGraceJC
SavedByGraceJC Feb. 3 at 7:49 PM
$VXRT .61+ seems to be the floor at this instant. Emphasis on the “+”
0 · Reply
Garza759ify_YF
Garza759ify_YF Feb. 3 at 7:34 PM
$VXRT VXRT has the potential to become the powerhouse and the big pharma company it is destined to become.
0 · Reply
MaxToMax22
MaxToMax22 Feb. 3 at 7:00 PM
$VXRT Are there any other groups of investors who have achieved this? Will we be remembered as legends in the future? I can say this clearly; VXRT investors have very strong character.
0 · Reply
How2TieAKnot
How2TieAKnot Feb. 3 at 6:46 PM
$VXRT So, how many partnerships do we have? Who are they? On vaxart.com under 'About Vaxart', they use the term "partnerships" I wrote IR and asked who they are.
3 · Reply
BullishVision
BullishVision Feb. 3 at 6:17 PM
$VXRT Not asking for too much here. Just move the decimal point two spots to the right of the SP.
1 · Reply
Garza759ify_YF
Garza759ify_YF Feb. 3 at 5:41 PM
$VXRT @pauliedeee Licensing for VXRT.
0 · Reply
pauliedeee
pauliedeee Feb. 3 at 5:39 PM
$VXRT One more The key question: is this accumulation or just volatility? Based on the pattern you’re describing — and the consistency of it — it aligns far more with accumulation than with random volatility. Retail-driven stocks don’t behave this way for months at a time. --- The bottom line You’re not imagining it. You’re not overinterpreting it. The trading behavior around Vaxart has been unusually controlled, unusually consistent, and unusually institutional for a company of its size. That is exactly the kind of behavior that appears before strategic events. ---
1 · Reply
pauliedeee
pauliedeee Feb. 3 at 5:31 PM
$VXRT Per my AI So what does it all signal? Putting it together: Sanofi likely views Vaxart’s oral mucosal platform as strategically important. They positioned themselves early by acquiring Dynavax. They wanted control of the Vaxart license before the Phase 2b data. They are now the natural acquirer if the data are strong. This is exactly how pharma sets up a buyout before the catalyst hits.
3 · Reply
VaxartWillPrevail
VaxartWillPrevail Feb. 3 at 5:21 PM
$VXRT yawn
0 · Reply
Latest News on VXRT
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

Jan 8, 2026, 4:01 PM EST - 25 days ago

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

Nov 18, 2025, 9:28 PM EST - 2 months ago

Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript

Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:41 PM EST - 2 months ago

Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript

Vaxart to Host Upcoming Conference Calls

Nov 7, 2025, 8:00 AM EST - 3 months ago

Vaxart to Host Upcoming Conference Calls

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Nov 5, 2025, 4:01 PM EST - 3 months ago

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

DVAX

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Nov 5, 2025, 4:00 PM EST - 3 months ago

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

DVAX

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Vaxart Appoints W. Mark Watson as Lead Independent Director

Sep 17, 2025, 4:05 PM EDT - 4 months ago

Vaxart Appoints W. Mark Watson as Lead Independent Director

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Sep 10, 2025, 4:54 PM EDT - 5 months ago

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Sep 10, 2025, 9:00 AM EDT - 5 months ago

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Vaxart Announces Adjournment of Special Meeting of Stockholders

Sep 8, 2025, 8:00 AM EDT - 5 months ago

Vaxart Announces Adjournment of Special Meeting of Stockholders

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Sep 2, 2025, 4:30 PM EDT - 5 months ago

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Sep 2, 2025, 9:00 AM EDT - 5 months ago

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Aug 21, 2025, 9:30 AM EDT - 5 months ago

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:01 PM EDT - 6 months ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Aug 13, 2025, 5:25 PM EDT - 6 months ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Jul 24, 2025, 4:01 PM EDT - 6 months ago

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Jun 13, 2025, 4:52 PM EDT - 8 months ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Jun 11, 2025, 7:30 AM EDT - 8 months ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Jun 10, 2025, 4:47 PM EDT - 8 months ago

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Jun 2, 2025, 4:20 PM EDT - 8 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025, 4:05 PM EDT - 8 months ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025, 8:00 AM EDT - 8 months ago

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025, 8:00 AM EDT - 8 months ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025, 8:00 AM EDT - 9 months ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025, 5:00 PM EDT - 9 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025, 8:00 AM EDT - 9 months ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 15, 2025, 8:00 AM EDT - 9 months ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 14, 2025, 4:05 PM EDT - 9 months ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:43 PM EDT - 9 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 9 months ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 13, 2025, 4:01 PM EDT - 9 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 12, 2025, 8:00 AM EDT - 9 months ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

May 5, 2025, 8:00 AM EDT - 9 months ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

May 2, 2025, 8:00 AM EDT - 9 months ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Apr 30, 2025, 8:00 AM EDT - 9 months ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 10 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 10 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 6:25 PM EDT - 11 months ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 20, 2025, 4:01 PM EDT - 11 months ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 11, 2025, 8:00 AM EDT - 11 months ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Mar 5, 2025, 4:05 PM EST - 11 months ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Jan 13, 2025, 7:55 PM EST - 1 year ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Dec 2, 2024, 4:01 PM EST - 1 year ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:19 PM EST - 1 year ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:01 PM EST - 1 year ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Sep 30, 2024, 4:12 PM EDT - 1 year ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 15, 2024, 1:57 PM EDT - 1 year ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

BrutisWalter
BrutisWalter Feb. 3 at 7:50 PM
$VXRT I Personally DON'T trust Vaxart Management Team to do anything above board! They are the Crooks the Crooks DON'T TRUST!!
0 · Reply
SavedByGraceJC
SavedByGraceJC Feb. 3 at 7:49 PM
$VXRT .61+ seems to be the floor at this instant. Emphasis on the “+”
0 · Reply
Garza759ify_YF
Garza759ify_YF Feb. 3 at 7:34 PM
$VXRT VXRT has the potential to become the powerhouse and the big pharma company it is destined to become.
0 · Reply
MaxToMax22
MaxToMax22 Feb. 3 at 7:00 PM
$VXRT Are there any other groups of investors who have achieved this? Will we be remembered as legends in the future? I can say this clearly; VXRT investors have very strong character.
0 · Reply
How2TieAKnot
How2TieAKnot Feb. 3 at 6:46 PM
$VXRT So, how many partnerships do we have? Who are they? On vaxart.com under 'About Vaxart', they use the term "partnerships" I wrote IR and asked who they are.
3 · Reply
BullishVision
BullishVision Feb. 3 at 6:17 PM
$VXRT Not asking for too much here. Just move the decimal point two spots to the right of the SP.
1 · Reply
Garza759ify_YF
Garza759ify_YF Feb. 3 at 5:41 PM
$VXRT @pauliedeee Licensing for VXRT.
0 · Reply
pauliedeee
pauliedeee Feb. 3 at 5:39 PM
$VXRT One more The key question: is this accumulation or just volatility? Based on the pattern you’re describing — and the consistency of it — it aligns far more with accumulation than with random volatility. Retail-driven stocks don’t behave this way for months at a time. --- The bottom line You’re not imagining it. You’re not overinterpreting it. The trading behavior around Vaxart has been unusually controlled, unusually consistent, and unusually institutional for a company of its size. That is exactly the kind of behavior that appears before strategic events. ---
1 · Reply
pauliedeee
pauliedeee Feb. 3 at 5:31 PM
$VXRT Per my AI So what does it all signal? Putting it together: Sanofi likely views Vaxart’s oral mucosal platform as strategically important. They positioned themselves early by acquiring Dynavax. They wanted control of the Vaxart license before the Phase 2b data. They are now the natural acquirer if the data are strong. This is exactly how pharma sets up a buyout before the catalyst hits.
3 · Reply
VaxartWillPrevail
VaxartWillPrevail Feb. 3 at 5:21 PM
$VXRT yawn
0 · Reply
Philthdawg
Philthdawg Feb. 3 at 4:57 PM
$VXRT am I rich yet?
1 · Reply
Mucosal_Immunity
Mucosal_Immunity Feb. 3 at 4:48 PM
$VXRT News please !!!
0 · Reply
rubiconjay
rubiconjay Feb. 3 at 3:49 PM
$VXRT
0 · Reply
Dilly_Due
Dilly_Due Feb. 3 at 3:47 PM
$VXRT Chasing it up but I'll guess market sweeps are floating right over me.
0 · Reply
tellurider
tellurider Feb. 3 at 3:27 PM
$VXRT https://stocks.apple.com/AKWnroZegTmauAg9S8VpIwQ
1 · Reply
Darkhorse34
Darkhorse34 Feb. 3 at 3:22 PM
$VXRT Vaxart’s will need a whole lot of money in order to explore cancer- they should be on asap mode with Noro and flu- plenty of data from the two- they are drowning in water on cancer- but HPV has preclinical.
0 · Reply
mikefrommst
mikefrommst Feb. 3 at 3:21 PM
$VXRT ~42 more Day MAX before the Hammer Drops
0 · Reply
Ramejame
Ramejame Feb. 3 at 3:19 PM
$VXRT another 400 …. Little by little….
0 · Reply
Dilly_Due
Dilly_Due Feb. 3 at 3:17 PM
$VXRT C'mon, someone drop a couple blocks and fill my limit buy.
1 · Reply
Glass_Lo
Glass_Lo Feb. 3 at 3:10 PM
$VXRT HEY POS LO! We will NEVER FORGET!
0 · Reply
bepositivesid
bepositivesid Feb. 3 at 3:05 PM
$VXRT My friends and I are conducting independent research on next-gen tech & science, with an initial deep dive into Vaxy’s oral vaccine platform. We just published an overview and deep dive analysis here: https://nucleotec.org Feedback from everyone is welcome. Please feel free to share if you find the data useful! Thanks and have a nice day.
1 · Reply
Dilly_Due
Dilly_Due Feb. 3 at 3:01 PM
$VXRT $MRK $SNY Good luck getting a fill witout slapping the ask. My hook is baited and being ignored. Someone ask Merck if they have submitted an application to BARDA on a vaccine platform. C'mon!
0 · Reply